Funding Opportunity: Understanding Relationships Between the Prenatal Development Period and Initiation of Islet Autoimmunity
Application Due Date: March 15, 2022
Full Grant Proposal Due: June 1, 2022
A goal of the Helmsley Charitable Trust’s (Helmsley) Type 1 Diabetes (T1D) Program is to support the discovery and development of interventions to prevent or delay the development of T1D. However, to identify new potential therapeutic approaches, the predisposing factors and environmental triggers that influence pathogenesis must be better understood.
Islet autoantibodies, which are predictive of clinical T1D, have been detected in very young children, indicating early-life events likely contribute to disease initiation. While a number of observational studies are investigating the links between early postnatal exposures and islet autoimmunity, few exist that have focused on the prenatal period of development. The complexity and resource-intensive nature of such studies has limited the ability to identify and investigate prenatal factors that contribute to initiation of islet autoimmunity in affected individuals. Understanding these factors may lead to new strategies to prevent and/or delay T1D.
To address this knowledge gap, the Helmsley T1D Program seeks to fund studies that aim to understand how the environment experienced during prenatal development influences development of islet autoimmunity during childhood.
For more information, visit here.
Funding Opportunity: Understanding and Therapeutically Emulating Examples Where Individuals Are Naturally Protected From Developing T1D
Application Due Date: March 15, 2022
Full Grant Proposal Due: June 1, 2022
A goal of the Helmsley Charitable Trust’s (Helmsley) Type 1 Diabetes (T1D) Program is to support the discovery and development of new therapies that will prevent or delay the development of T1D.
T1D is a complex autoimmune disease that eliminates insulin-producing beta cells from the pancreas. To identify therapies that have the highest likelihood of preventing or delaying it, the research field needs to understand the disease’s predisposing factors, triggers, and elements that affect its pathogenesis. Understanding these early drivers—and, perhaps more compellingly, what can override these early drivers—could lead to new discoveries into therapy targets or guide new intervention strategies to halt the disease.
In T1D, certain groups of individuals are protected from disease. These natural cases of protection include individuals with a certain genetic background and individuals born to a mother with T1D. These “clinical trials run by nature” show that the factors that drive T1D can be overridden. Furthermore, if this natural protection can by better understood, new therapies might be able to emulate their effects.
Despite a potentially high impact for people with T1D, scientific research into protection is challenged by lack of access to human samples, high costs associated with studying human samples, and the large amount of resources needed to establish new cohorts of individuals to collect samples.
To address this challenge, the Helmsley T1D Program seeks to support studies that aim to understand and/or therapeutically emulate natural protection from T1D.
For more information, visit here.
RFA-DK-20-032
Pilot and Feasibility Studies to Facilitate the Use of Diabetes Self-Management Education and Support to Improve Diabetes Care (R34 Clinical Trial Required)
Letter of Intent Due Date(s): May 22, 2021; May 22, 2022; and May 22, 2023
Application Due Date(s): June 22, 2021; June 22, 2022; June 22, 2023
The purpose of this funding opportunity announcement (FOA) is to test an innovative and pragmatic approach to address barriers to and facilitate greater use of diabetes self-management education and support (DSMES) by people living with diabetes mellitus. Research applications should engage key stakeholders in cultivating a practical and sustainable strategy with the potential for dissemination. The pilot trial of the proposed strategy should be designed to generate preliminary data in support of a future, full-scale trial to study broader dissemination and implementation to expand the use of DSMES.
For more information:
https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-20-032.html
Funding Opportunity: 2022 dkNET New Investigator Pilot Program in Bioinformatics
Letter of Intent Due Date: January 28, 2022
Application Due Date: February 28, 2022
Are you an early stage and new investigator seeking to apply computationally-intensive methods to important questions in Diabetes, Endocrinology and Metabolic Disease (DEMD) research? Check out the dkNET New Investigator Pilot Program in Bioinformatics! These awards will provide funding for preliminary studies that can serve as a foundation for the development of future grant applications in DEMD-focused topic areas.
dkNET Pilot Award applications should focus on applying computational and/or modeling approaches, whether data-driven, mechanism-driven, or integrated, to compelling research problems in diabetes, endocrinology and related metabolic disorders. Consistent with these goals, this program will support projects focused on a wide array of topics including, but not limited to:
- Metabolic modeling of known and unknown pathway kinetics and compartmentalization in diabetes and/or endocrine or metabolic disorders;
- Network and systems biology of intra and intercellular regulation and inter-tissue and organ homeostasis focused on etiology, diagnosis, prognosis or responses to treatment, including computational approaches to identify biomarkers capable of tracking disease process or progress;
- Structural biology/informatics and chemical informatics of endocrine and metabolic pathways in diabetes, endocrinology and related metabolic diseases;
- AI-assisted image analysis and spatial omics of organs or tissues of relevance to diabetes or metabolic disease;
- Computational characterization of the normal or abnormal development of involved organs such as the formation of pancreatic islets;
- Innovative approaches to characterize and understand type 2 diabetes heterogeneity;
- Clinical informatics including curation, modeling and integration of data from EHR, medical devices, wearables and smartphone apps in diabetes prevention, care and management;
- Data science approaches to understand, reduce, and prevent diabetes-related health disparities, including new analysis through social networks and structure;
- The mechanisms for dysregulated glycemia, or diabetes in increased susceptibility or altered course of COVID-19 infection, and for metabolic dysfunction, diabetes, or other endocrine diseases that result from COVID-19 infection.
Of particular interest are projects that can leverage and expand the utility of existing large datasets developed in NIDDK projects and programs. For examples, see the dkNET webpage at NIDDK-specific-repositories. Research designed to address important research questions through the development of new analytical tools, or through novel secondary analyses of existing datasets are encouraged.
More information: https://dknet.org/about/new-investigator-pilot
NIDDK Workshop “Integrated Physiology of the Exocrine and Endocrine Compartments in Pancreatic Diseases”
March 14-15, 2022
Bethesda, MD
Meeting Objectives
The goal of this 1.5-day workshop will be to gather clinical and basic science investigators who are interested in diseases of the exocrine and/or endocrine pancreas and in achieving an understanding of how the two compartments interact in disease. This workshop will provide an opportunity for investigators in exocrine diseases to come together with those studying islets in diabetes as a means to foster interdisciplinary discussion and identify areas for advancement.
Registration Deadline
March 1, 2022
Abstract Deadline
January 28, 2022
JDRF is requesting applications for the following three opportunities:
1. Novel Immune Strategies to Enhance Beta Cell Replacement Therapies for T1D
Key Dates
September 27, 2021 – RFA Launch
October 25, 2021 – LOI Deadline
November 8, 2021 – Notification of Invitation to Full Proposal
December 20, 2021 – Full Proposal Submission Deadline
April 2022 – Response to Applicants
July 2022 – Earliest Start Date
2. Novel Approaches to Address Disordered Eating and Eating Disorders in Type 1 Diabetes
Key Dates
September 27, 2021 – RFA Launch
October 27, 2021 – LOI Deadline
November 3, 2021 – Notification of Invitation to Full Proposal
December 6, 2021 – Full Proposal Submission Deadline
April 2022 – Response to Applicants
June 2022 – Earliest Start Date
3. Clinical Trials to Advance Therapies for Nephropathy and Cardiovascular Disease in Type 1 Diabetes
Key Dates
September 27, 2021 – RFA Launch
November 8, 2021 – LOI Deadline
November 22, 2021 – Notification of Invitation to Full Proposal
January 5, 2022 – Full Proposal Submission Deadline
May 2022 – Response to Applicants
August 2022 – Earliest Start Date
Notice of Special Interest: Administrative Supplements to Support Emerging Physician-Scientists to Develop Research Expertise in Diabetes, Endocrinology and Metabolic Disease
(NOT-DK-21-022)
Release Date: July 19,2021
First Available Due Date: February 3, 2022
Expiration Date: February 4, 2023
Purpose
The supplement is intended to allow candidates to expand their research experience to help them transition beyond their clinical training to the next stage of their research careers as physician-scientists.
The purpose of the NIDDK’s Division of Diabetes, Endocrinology and Metabolic Diseases (DDEMD) Administrative Supplement Program is to enable additional clinical perspectives to be brought to on-going research projects within the Division’s mission and to enhance the research expertise of selected physicians.The program will provide supplementary funds to support advanced research opportunities for exceptional emerging physician-scientists (hereafter, “candidates”) holding the MD or equivalent or MD/PhD degrees, and who are early in their research careers.
Administrative supplements must support work within the scope of a currently funded basic and/or clinical DDEMD research project. All applicants are strongly encouraged to discuss potential requests with the NIDDK DDEMD program director of the award for which they wish to submit a supplement application. See https://www.niddk.nih.gov/about-niddk/staff-directory/by-office/division-diabetes-endocrinology-metabolic-diseases for DDEMD program director contact information.
Applicants must describe:
- The commitment of the Program Director/Principal Investigator (PD/PI) and other faculty (if applicable) to provide appropriate guidance and supervision of the candidate’s research experience
- The candidate’s qualifications
- How the candidate’s involvement in the research project will advance the project and contribute to his/her research expertise
For more information, https://grants.nih.gov/grants/guide/notice-files/not-dk-21-022.html
The American Diabetes Association Cardiovascular-Metabolic Fellowship Awards
The American Diabetes Association, through support provided by Pfizer, Inc., is now requesting applications for postdoctoral fellows proposing basic, clinical and translational research focused on cardiovascular disease in the context of diabetes. The application deadline is October 26, 2020 for January 1, 2021 funding. The Association intends to fund 2 fellowships from the ADA Cardiovascular-Metabolic Fellowship Awards request for applications.
For more information https://professional.diabetes.org/content/targeted-rfas
Changes in the NIH study sections that are part of CSR’s Endocrinology, Metabolism, Nutrition, and Reproduction (EMNR) Integrated Review Group.
ADA Cardiovascular-Metabolic Fellowship Awards RFA(link is external)
Five current study section panels in the EMNR cluster will end after this fall:
- Cellular Aspects of Diabetes and Obesity Study Section(CADO)
- Clinical and Integrative Diabetes and Obesity Study Section (CIDO)
- Integrative Nutrition and Metabolic Processes Study Section (INMP)
- Integrative Physiology of Obesity and Diabetes Study Section (IPOD)
- Molecular and Cellular Endocrinology Study Section (MCE)
Five new study sections will launch in early 2021 (to review applications submitted for the October/November 2020 deadlines):
- Basic Mechanisms of Diabetes and Metabolism Study Section
- Cell Signaling and Molecular Endocrinology Study Section
- Human Studies of Diabetes and Obesity Study Section
- Nutrition and Metabolism in Health and Disease Study Section
- Pathophysiology of Obesity and Metabolic Disease Study Section
More information is here and will be updated in the future: https://public.csr.nih.gov/StudySections/DPPS/EMNR
NIDDK Catalyst Award (DP1 Clinical Trial Not Allowed)
(RFA-DK-20-024)
National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Date(s): January 06, 2021
The NIDDK Catalyst Award is designed to complement NIDDK’s traditional, investigator-initiated grant programs by supporting individual scientists who propose pioneering and transformational studies in topic areas of interest to NIDDK’s Division of Diabetes, Endocrinology and Metabolic Diseases, and to NIDDK’s Division of Digestive Diseases and Nutrition. Applications should be focused on major scientific challenges, and have the potential to produce an unusually high impact on diseases and conditions that are central to the mission of these two divisions within NIDDK. To be considered responsive to this initiative, the proposed research should reflect new and novel scientific directions that are distinct from concepts and approaches being pursued in the investigator’s research program or elsewhere.
For more information NIDDK Catalyst Award (DP1 Clinical Trial Not Allowed)
Mechanistic Studies of the Interaction between SARS-CoV-2/COVID-19 and Diseases and Organ Systems of Interest to NIDDK (R01 Clinical Trial Optional)
(RFA-DK-20-021)
National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Date(s): December 16, 2020
Purpose:
The purpose of this Funding Opportunity Announcement (FOA) is to support basic and clinical mechanistic research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) susceptibility, routes of infection, course of disease, morbidity and mortality in people with pre-existing diseases, or adverse acute or chronic outcomes in organs, tissues, and biological systems of specific interest to NIDDK. These include diabetes and other metabolic diseases, obesity, and endocrine, digestive, liver, pancreas, kidney, urological, and hematologic tissues and diseases.
NIDDK plans to host a pre-receipt informational webinar for researchers interested in applying for RFA DK-20-021. It will take place on Monday, November 9, 2020 at 3:00pm ET. Please register by writing to michael.mensah@nih.gov with your name, affiliation and email address.
For more information: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-20-021.html
HIRN Emerging Leaders in T1D Award (2020)
Key Dates
Posted Date June 15, 2020
Letter of Intent Due Date September 30, 2020
Application Due Date October 30, 2020
Scientific Review November 2020/December 2020
Start Date February 1, 2021
Expiration Date October 31, 2020
HIRN Emerging Leaders in T1D Award (2020)
Notice of Specialist Interest (NOSI):
Availability of Funds for Competitive Revision Applications to Conduct Research with a Focus in Chronic Disease and the Reduction of Health Disparities Within the Mission of NIDDK (R01, U01, U24, P30, U54)
NOT-DK-20-012
NIDDK
For more information: https://grants.nih.gov/grants/guide/notice-files/NOT-DK-20-012.html
Small R01s for Clinical Trials Targeting Diseases within the Mission of NIDDK (R01 Clinical Trial Required)
PAS-20-160
This Funding Opportunity Announcement encourages the submission of pilot and feasibility clinical trials conducted in humans that will lay the foundation for larger clinical trials related to the prevention and/or treatment of diseases and conditions within the mission of NIDDK. The program will support small, short-term clinical trials in humans to acquire preliminary data regarding the effects of the intervention, as well as feasibility data related to recruitment and retention, and study conduct. Applications for clinical trials submitted under this FOA should have clearly described aims and objectives, and have a high likelihood that the trial findings will lead to more definitive, hypothesis-driven trialsto improve understanding, diagnosis, prevention or treatment of the diseases studied and have the potential to impact clinical practice and/or public health. Preliminary data regarding intervention efficacy are not required.
For more information: https://grants.nih.gov/grants/guide/pa-files/PAS-20-160.html
Deadline Extended: May 18, 2020
Call for Novel Studies in Diabetes and Obesity
to Eliminate Disparities:
Team Science Across the Translational Continuum
Washington University Center for Diabetes Translation Research (CDTR),
Nutrition Obesity Research Center (NORC), Diabetes Research Center (DRC),
Institute of Clinical and Translational Sciences (ICTS), and Institute for Public Health (IPH)
The major objective of this rapid funding mechanism is to stimulate transdisciplinary team research to advance novel approaches in the prevention and treatment of diabetes/obesity with the goal of eliminating disparities. This opportunity will support novel research directions targeting the interaction of social determinants with biological and environmental mechanisms through which social disadvantage increases diabetes/obesity burden and inform new leverage points for intervention.
Awards will provide up to $60,000 direct costs, per year, for one or two years. The second year of funding will depend on demonstrating adequate progress during the first year. Preference will be given to projects focusing primarily on the St. Louis region.
Application timeline:
• Electronic notification of intent due by May 4, 2020 (optional)
• Full proposals are due May 18, 2020 (5:00pm)
Additional application details are attached and can be found at https://cdtr.wustl.edu/pilot-feasibility/special-request-for-applications/.
For more information contact Allison Phad, CDTR Research Manager, at allisonphad@wustl.edu.
Patient-oriented Research to Mitigate Health Disparities and Lessen the Burden of Chronic Diseases Within the Mission of NIDDK (R01 Clinical Trial Optional)
(RFA-DK-20-015)
Application Receipt Date(s): May 22, 2020 No late applications will be accepted for this Funding Opportunity Announcement.
Shared Instrumentation for Animal Research (SIFAR) Grant Program (S10 Clinical Trial Not Allowed)
(PAR-20-112)
Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
Application Receipt Date(s): June 1, 2020
Shared Instrumentation Grant (SIG) Program (S10 Clinical Trial Not Allowed)
(PAR-20-113)
Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
National Institute of General Medical Sciences
Application Receipt Date(s): June 1, 2020
High-End Instrumentation (HEI) Grant Program (S10 Clinical Trial Not Allowed)
(PAR-20-114)
Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
National Institute of General Medical Sciences
Application Receipt Date(s): June 1, 2020
The 2020 DiaComp Pilot & Feasibility Program
Applications of 5 pages requesting up to $100,000 for one year are due June 10, 2020.
Current areas of interest include, but are not limited to:
• Role of the Microbiome in Diabetic Complications
• Targeted Delivery of Therapeutics
• Imaging and Tissue Interrogation
• Sex Differences
• Autonomic Neuropathy
• Pre-clinical Testing
Who is eligible to apply?
Applications are accepted from domestic (US) institutions/ organizations.
Non‐domestic (non‐U.S.) Entities (Foreign Institutions) are NOT eligible to apply.
What funds are available for P&F Projects?
Applicants may request up to $100,000 (direct + indirect costs) Total Costs for one year. The number of awards will depend upon the number, quality, duration, and cost of the applications received. Awards will be made as subcontracts from the DiaComp Coordinating Unit (CU) at Augusta University and NOT directly by the NIH.
Timetable for P&F Application Submissions.
June 10th Deadline for applications submitted to the DiaComp CU.
Oct. 1st Estimated Start Date for DiaComp P&F Project funding.
Contact Information
For more detailed information, please go to http://www.diacomp.org/shared/pilotFeasibility.aspx
dkNET New Investigator Pilot Program in Bioinformatics
Key Dates
Posted Date November 01, 2019
Letter of Intent Due Date January 14, 2020
Application Due Date February 14, 2020
Scientific Review March-April 2020
Start Date May 2020
Expiration Date February 15, 2020
Submission Site
For further information and submission instructions please go to the MMPC submissions portal.
Introduction
As high throughput technologies become routine for individual laboratories in biomedical research, there is a growing need to develop a workforce that can use and further refine the computational approaches needed to interrogate complex data. This pilot program, through the NIDDK Information Network (dkNET), is designed to encourage new investigators to apply innovative bioinformatics approaches to important research problems in Diabetes, Endocrinology and Metabolic Diseases (DEMD). The dkNET New Investigator Pilot Program is designed to: (i) facilitate the ability of Early Stage and New Investigators with computational and bioinformatics expertise to pursue research questions in DEMD, or (ii) allow Early Stage and New PIs currently pursuing DEMD-related research to explore incorporating computational, statistical, and/or bioinformatics approaches into their research projects.
NIDDK Funding Opportunity Announcements
Bioinformatics Interdisciplinary Predoctoral Fellowship in Diabetes, Endocrinology and Metabolic Diseases (F31)
(PAR-19-378)
National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Date(s): Standard dates apply All applications are due, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Bioinformatics Interdisciplinary Postdoctoral Fellowship in Diabetes, Endocrinology and Metabolic Diseases (F32)
(PAR-19-379)
National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Date(s): Standard dates apply All applications are due, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Notice of Special Interest: Alzheimer’s-focused administrative supplements for NIH/NIDDK grants that are not focused on Alzheimer’s disease
Notice Number:
NOT-DK-20-009
For details, see: https://grants.nih.gov/grants/guide/notice-files/NOT-DK-20-009.html
Active awards with project end dates in FY 2021 or later are eligible. The award may not be in terminal no cost extension or going into no cost extension in FY 2020. As administrative supplements, the work proposed needs to be within the scope of the research or training that is already supported.
Application due date: March 6, 2020 by 5:00 PM local time of applicant organization. To be considered for funding, applicants must carefully follow the application instructions in the NOSI.
Applications for this initiative must be submitted using PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional).
Workshop on the Physiology of the Weight Reduced State
Workshop on the Physiology of the Weight Reduced State
June 3 – 4, 2019
Bethesda, MD
Background
Preventing regain of lost weight is the most difficult challenge in the treatment of obesity. Various physiological adaptations occur that make maintaining weight loss difficult by reducing energy expenditure and increasing energy intake.
Objectives
The overarching goal of this workshop is to explore the mechanisms and integrative physiology of adaptations in appetite, energy expenditure, and thermogenesis (metabolic adaptation) that occur in the weight reduced state and may oppose weight loss maintenance.
The workshop will include—
- Clinical experience with weight reduction and weight loss maintenance versus regain across interventions
- Factors opposing weight loss maintenance
- Factors affecting energy intake in the weight reduced state, including neural and endocrine regulation and the integration of homeostatic and hedonic pathways along with microbiome links
- Metabolic adaptation/adaptive thermogenesis and tissue-specific roles and mechanisms
- Strategies for understanding the physiology of the weight reduced state and improving weight loss maintenance
- Factors potentially responsible for physiological variability in weight maintenance versus regain
Registration Deadline
May 25, 2019